Prosight Management, LP Bristol Myers Squibb CO Transaction History

Prosight Management, LP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 13, 2021	SELL	$61.91 - $67.42 $5.92 Million - $6.45 Million	-95,600 Closed	0 $0
Q1 2021 May 14, 2021	SELL	$59.34 - $66.74 $4.36 Million - $4.9 Million	-73,400 Reduced 43.43%	95,600 $6.04 Million
Q4 2020 Feb 12, 2021	SELL	$57.74 - $65.43 $952,710 - $1.08 Million	-16,500 Reduced 8.89%	169,000 $10.5 Million
Q3 2020 Nov 13, 2020	BUY	$57.43 - $63.64 $3.88 Million - $4.3 Million	67,500 Added 57.2%	185,500 $11.2 Million
Q2 2020 Aug 14, 2020	BUY	$54.82 - $64.09 $6.47 Million - $7.56 Million	118,000 New	118,000 $6.94 Million
Q1 2020 May 15, 2020	SELL	$46.4 - $67.43 $375,840 - $546,183	-8,100 Closed	0 $0
Q4 2019 Feb 14, 2020	SELL	$49.21 - $64.19 $14.6 Million - $19.1 Million	-296,800 Reduced 97.34%	8,100 $520,000
Q3 2019 Nov 14, 2019	SELL	$42.77 - $50.71 $4.52 Million - $5.35 Million	-105,590 Reduced 25.72%	304,900 $15.5 Million
Q2 2019 Aug 14, 2019	BUY	$44.62 - $49.34 $5.69 Million - $6.29 Million	127,490 Added 45.05%	410,490 $18.6 Million
Q1 2019 May 15, 2019	BUY	$45.12 - $53.8 $12.8 Million - $15.2 Million	283,000 New	283,000 $13.5 Million

2,428

1.5B

29.7M

32.2M

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $113B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

Get notified when there are updates to the investment portfolio of Prosight Management, LP, based on Form 13F filings with the SEC.

Stay updated on Prosight Management, LP with notifications on news.